Document is current
Any future updates will be listed below
-
Authors
Ando, Katsuyoshi https://orcid.org/0000-0003-3500-5488
Kashima, Shin https://orcid.org/0000-0001-8309-4281
Sakatani, Aki https://orcid.org/0000-0001-7975-2413
Konishi, Hiroaki https://orcid.org/0000-0002-6477-721X
Maemoto, Atsuo https://orcid.org/0000-0002-9182-8502
Ito, Takahiro https://orcid.org/0000-0001-5228-4840
Taruishi, Masaki https://orcid.org/0009-0008-8602-8958
Ishiguro, Kaori https://orcid.org/0009-0001-0322-4507
Fujiya, Mikihiro https://orcid.org/0000-0002-4321-7774
-
Funding
Funding for this research was provided by:
Takeda Pharmaceutical Company
- License Information
-
More Information
Article History
Received: 17 February 2025
Accepted: 31 December 2025
First Online: 17 January 2026
Declarations
:
: The study was conducted in accordance with the Declaration of Helsinki and the International Council for Harmonisation and Good Clinical Practice guidelines for the conduct of clinical research. The study was approved by the Hokkaido University Certified Review Board (approval no. 020-004), and all patients provided written informed consent before initiation of study procedures.
: Not applicable.
: Katsuyoshi Ando reports funding for the present work from Takeda Pharmaceutical Co. Ltd.; grants from Pfizer Inc.; and honoraria for lectures from AbbVie GK, EA Pharma Co. Ltd., Janssen Pharmaceutical K.K., JIMRO Co. Ltd., Mitsubishi Tanabe Pharma Co. Ltd., Mochida Pharmaceutical Co. Ltd., Pfizer Inc., and Takeda Pharmaceutical Co. Ltd. Shin Kashima reports funding for the present work from Takeda Pharmaceutical Co. Ltd. Aki Sakatani reports funding for the present work from Takeda Pharmaceutical Co. Ltd. Hiroaki Konishi reports funding for the present work from Takeda Pharmaceutical Co. Ltd. Atsuo Maemoto reports funding for the present work from Takeda Pharmaceutical Co. Ltd.; grants or contracts from AbbVie GK, Eli Lilly Japan K.K., Gilead Sciences Inc., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Co. Ltd., Pfizer R&D Japan G.K., and Takeda Pharmaceutical Co. Ltd.; payments or honoraria for lectures, presentations, speaker bureaus, manuscript writing, or educational events from AbbVie GK, EA Pharma Co. Ltd., Eli Lilly Japan K.K., Janssen Pharmaceutical K.K., Nippon Kayaku Co. Ltd., and Takeda Pharmaceutical Co. Ltd. Takahiro Ito reports funding for the present work from Takeda Pharmaceutical Co. Ltd.; and grants or contracts from AbbVie Inc., Eli Lilly Co. Ltd., Gilead Sciences Inc., Janssen Pharmaceutical K.K., Pfizer Japan Inc., and Takeda Pharmaceutical Co. Ltd. Masaki Taruishi reports funding for the present work from Takeda Pharmaceutical Co. Ltd. Kaori Ishiguro was an employee of Takeda Pharmaceutical Co. Ltd. at the time this study was conducted. Mikihiro Fujiya reports funding for the present work from Takeda Pharmaceutical Co. Ltd.; and honoraria for speaker bureaus from Takeda Pharmaceutical Co. Ltd.
